Breast Cancer Debate of the Year 2023

Rewatch the Breast Cancer Debate of the Year 2023

On Friday 26 January 2024, the Institute Jules Bordet and the Belgian Society of Medical Oncology (BSMO) represented by its Breast Cancer Task Force organised the “Breast Cancer Debate of the Year”. The Friday evening session included debates of great interest for clinical practice as well as educational lectures. You can rewatch the lectures here below.

Session 1:
The use of Gene Expression Profile in a 42 y old patient with stage II luminal BC

In favour: Jeroen Mebis (UHasselt)
Not in favour: Michael Ignatiadis (Institut Jules Bordet – HUB)

Session 2:
Stage III luminal BC in BRCA mutated patient who did not reach PCR: Olaparib or CDK4/6 inhibitor

Olaparib: Caroline Duhem (CHL)
CDK4/6 inhibitors: Hannelore Denys (UZ Gent)

Session 3:
Immediate breast reconstruction

In favour: Marian Vanhoeij (UZ Brussel)
Not in favour: Gerd Fabré (UZ Leuven)

Session 4:
Post surgery systemic therapy in pCR patients after CPI (TNBC)/HER2 therapies (HER2 + tumors)

Hans Wildiers (UZ Leuven)

Session 1: The use of Gene Expression Profile in a 42 y old patient with stage II luminal BC

Session 2:Stage III luminal BC in BRCA mutated patient who did not reach PCR: Olaparib or CDK4/6 inhibitor

Session 3: Immediate breast reconstruction

Session 4:Post surgery systemic therapy in pCR patients after CPI (TNBC)/HER2 therapies (HER2 + tumors)

Session 1:
The use of Gene Expression Profile in a 42 y old patient with stage II luminal BC

Session 2:
Stage III luminal BC in BRCA mutated patient who did not reach PCR: Olaparib or CDK4/6 inhibitor

Session 3:
Immediate breast reconstruction

Session 4:
Post surgery systemic therapy in pCR patients after CPI (TNBC)/HER2 therapies (HER2 + tumors)